1-800-452-8106      Contact      Careers
Emdeon  EMDEON  I-WEB  PATIENT BILL PAY

Laboratory Test Detail

Last Updated: May 27, 2023 @ 9:13 am

2261

PSA, Ultrasensitive Total and Free

Specimen:Collect:
  • One SST

Also Acceptable:
  • One Green Top (Li Heparin)
  • One Red Top
Submit:
  • 1 mL (Min:0.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.

Also Acceptable:
  • 1 mL (Min:0.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling:
  • Allow specimen to clot completely at room temperature
  • Avoid Repeated Freeze/Thaw Cycles
  • Minimize air exposure
  • Separate from cells ASAP
  • For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
    Ultrasensitive portion is equivalent to Total PSA, Results below 1.0 ng/mL will report out to the thousandths decimal place.
Rejection Criteria:
  • Grossly Hemolyzed Samples
Stability:Ambient: 8 Hour(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable
Methodology:
  • Electrochemiluminescence Immunoassay (ECLIA)
Performed:Mon-Fri
Reported:1-3 Day(s)
CPT Codes:
  • 84153
  • 84154
Interpretive Data:Please see report for interpretive data.
The Roche e801 PSA electrochemiluminescent immunoassay is the test methodology used. Results obtained with different assay methods or kits cannot be used interchangeably. The Roche e801 PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche e801 PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.

Probability of finding prostate cancer on needle biopsy by age in years

Age in Years
% fPSA ratio 50-59 60-69 >69
<11 49.2 % 57.5 % 64.5 %
11-18 26.9 % 33.9 % 40.8 %
19-25 18.3 % 23.9 % 29.7 %
> 25 9.1 % 12.2 % 15.8 %

Biotin in specimens taken from patients on high-dose biotin therapy or supplements may interfere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Components:
  • 2147 - PSA, ULTRASENS
  • 2247 - FREE PSA
  • 2248 - % FREE PSA
Print Friendly, PDF & Email

Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.